$41.33
Today
as of Jul 22, 16:53 ET
Last 30 days
Recent Press Releases & News
What Does the Sale of Rapport Therapeutics Stock Worth Over $400,000 by the Chief Operating Officer Mean for Investors?
Leerink Partners Initiates Rapport Therapeutics at Outperform With $52 Price Target
Is Rapport Therapeutics, Inc. (RAPP) A Good Stock To Buy Now?
Overview
52-week range
$11
$42
97% of range
Avg surprise (last 3)
+16.8%
Avg reaction (last 2)
+6.0%
100% positive
Latest IV / EM
80%
EM ±18.2% · $43 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $-0.42 | $-0.56 | +25.0% | +38.2% | +7.7% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.71 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-0.75 | $-0.87 | +13.8% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-0.68 | $-0.77 | +11.7% | — | +4.2% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.50 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-1.70 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-11.07 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-5.70 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-4.45 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 6, 2026 | Jun/2026 | OTHER | -$0.88 | -$0.75 | -17.3% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $20M | — | — | — | $0 | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-24M | — | $-30M | $-29M | $-27M | — | $-22M | $-21M |
| Net income | $-20M | — | $-27M | $-27M | $-24M | — | $-18M | $-18M |
| EPS (diluted) | $-0.42 | — | $-0.71 | $-0.75 | $-0.68 | — | $-0.50 | $-1.70 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $78M | $53M | $251M | $55M | $58M | $57M | $39M | $110M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $485M | $499M | $521M | $270M | $291M | $310M | $326M | $341M |
| Total assets | $498M | $512M | $535M | $285M | $302M | $315M | $331M | $346M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $26M | $28M | $24M | $22M | $16M | $10M | $8M | $9M |
| Total equity | $472M | $485M | $512M | $264M | $286M | $305M | $323M | $337M |